Improving Access to Rare Disease Treatments: Subsidy, Pricing, and Payment Schemes II: Consortium Price, No Cure No Pay: Subsidize Only Patients When the Price Is High, Only the Manufacturer When LowResearch Paper
A rare disease affects few patients, so a drug for it has a small market and its research and development (R&D) cost is spread over few sales. Governments respond with two kinds of subsidy: cost subsidies that pay part of the manufacturer's R&D bill (orphan drug programmes), and price subsidies that pay part of what each patient is charged. At the same time…